Australia Markets closed

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.1500+0.0100 (+0.32%)
As of 01:10PM EDT. Market open.

bluebird bio, Inc.

60 Binney Street
Cambridge, MA 02142
United States
339 499 9300

Full-time employees518

Key executives

NameTitlePayExercisedYear born
Mr. Andrew ObenshainPres, CEO & Director842.85kN/A1975
Mr. Thomas J. KlimaChief Commercial Officer & COO509.7kN/A1972
Mr. Christopher Krawtschuk CPACFO, Principal Accounting Officer & TreasurerN/AN/A1974
Mr. Joseph D. Vittiglio Esq., J.D.Chief Bus. & Legal OfficerN/AN/A1972
Jess RowlandsHead of Corp. CommunicationsN/AN/AN/A
Ms. Andrea WaltonChief People OfficerN/AN/AN/A
Ms. Melissa BonnerSr. VP of ResearchN/AN/AN/A
Mr. Richard Colvin M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Mr. Kasra KasraianSr. VP of Technical Devel. & OperationsN/AN/AN/A
Mr. Scott ShoemakerSr. VP of QualityN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Corporate governance

bluebird bio, Inc.’s ISS governance QualityScore as of 1 February 2023 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.